Results 241 to 250 of about 545,624 (314)

Panitumumab labeled with Auger electron-emitting ^197gHg/^197mHg: cytotoxicity on human breast cancer cells and tumour and normal tissue uptake in mice with EGFR-overexpressing breast cancer xenografts. [PDF]

EJNMMI Radiopharm Chem
Chu ACK, Ho F, Chan C, Cai Z, Ganga-Sah Y, Randhawa P, Ramogida CF, Radchenko V, Reilly RM.   +8 more
europepmc   +1 more source

Untersuchung von Anti‐Glykan‐Antikörpern und Erforschung ihres medizinischen Potenzials mithilfe synthetischer Glykane

Angewandte Chemie, EarlyView.
Anti‐Glykan‐Antikörper spielen sowohl bei Gesundheit als auch bei Krankheit eine wesentliche Rolle. Der Zugang zu neuartigen Glykanstrukturen ermöglicht Fortschritte bei der Antikörpercharakterisierung für die Entdeckung von Biomarkern, die Antikörperentwicklung und das Impfstoffdesign.
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Acquired <i>ROS1</i> Intragenic Rearrangements as a Resistance Mechanism in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Case Series. [PDF]

Curr Oncol
Liu PT, Chen YL, Chen WL, Ho CL, Lee CH.
europepmc   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, EarlyView.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Are lazertinib and osimertinib comparable for treating advanced <i>EGFR</i>-mutant non-small cell lung cancer?-insights and limitations from the MARIPOSA study. [PDF]

J Thorac Dis
Urbanska EM, Santoni-Rugiu E, Grauslund M, Sørensen JB.   +3 more
europepmc   +1 more source

ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response. [PDF]

JCO Precis Oncol
Peshin S, Saj F, Kasi PM, David F, Szklaruk J, Kimana Q, Pant S, Lee SS, Knox JJ, Borad MJ, Javle M.   +10 more
europepmc   +1 more source

Recent Advances in Virus–Host Interactions, Antiviral Bioactive Compounds, and Breeding for Disease Resistance of Porcine Epidemic Diarrhea Virus

Animal Research and One Health, EarlyView.
Basic research on the PEDV infection cycle and virus–host interactions advances the development of anti‐PEDV drugs and disease‐resistant breeding and helps strengthen disease prevention and control while reducing economic losses in the swine industry.
Heyong Wu, Aosi Qi, Shuyu Zhong, Haozhen Du, Shimeng Guo, Hongsheng Ouyang, Hongming Yuan, Daxin Pang, Zicong Xie   +8 more
wiley   +1 more source

The impact of left ventricular assist devices on kidney function: a systematic review and meta-analysis. [PDF]

Egypt Heart J
Hosseini A, Darouei B, Amani-Beni R, Shafie D, Mazaheri-Tehrani S, Haghighatpanah MA, Heidarpour M, Amini-Salehi E, Hashemi SM, Harrison A, Hameed I, Reid CM, Movahed MR.   +12 more
europepmc   +1 more source

Investigating the Shared Mechanisms of Endocrine-Disrupting Chemicals in Urogenital Tumors. [PDF]

Biology (Basel)
Liu C, Wu S, Zhou R, Xiao S, Yang C.
europepmc   +1 more source

A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST)

American Journal of Hematology, EarlyView.
Kenneth I. Ataga, Pablo Bartolucci, Santosh L. Saraf, Vimal K. Derebail, Adlette Inati, Jeffrey D. Lebensburger, Laurie DeBonnett, Rodolfo D. Cancado, Claire C. Sharpe   +8 more
wiley   +1 more source